Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
China · Delayed Price · Currency is CNY 9.56
+0.15 (1.59%)
Feb 13, 2026, 3:07 PM CST
Xiangxue Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,451 | 1,839 | 2,273 | 2,166 | 2,930 | 2,923 |
Other Revenue | 19.76 | 19.76 | 26.76 | 20.75 | 40.87 | 148.61 |
| 1,471 | 1,859 | 2,299 | 2,187 | 2,971 | 3,072 | |
Revenue Growth (YoY) | -30.11% | -19.16% | 5.13% | -26.38% | -3.30% | 10.26% |
Cost of Revenue | 1,178 | 1,451 | 1,556 | 1,654 | 2,229 | 2,093 |
Gross Profit | 292.56 | 407.61 | 743.33 | 533.38 | 741.4 | 979.12 |
Selling, General & Admin | 461.09 | 522.29 | 583.02 | 602.22 | 659.02 | 583.58 |
Research & Development | 75.15 | 79.39 | 89.76 | 94.79 | 90.6 | 66.99 |
Other Operating Expenses | 53.22 | 7.08 | 12.83 | 10.44 | 13.6 | 10.5 |
Operating Expenses | 622.02 | 641.53 | 693.66 | 708.73 | 763.79 | 667.27 |
Operating Income | -329.46 | -233.92 | 49.67 | -175.35 | -22.39 | 311.85 |
Interest Expense | -268.62 | -232.85 | -237.06 | -213.2 | -202.06 | -130.29 |
Interest & Investment Income | - | 2.78 | 1.2 | 51.24 | 41.84 | 34.78 |
Currency Exchange Gain (Loss) | -0 | -0 | -0 | 0.08 | 0.01 | 0 |
Other Non Operating Income (Expenses) | 32.39 | -0.71 | -70.83 | -23.79 | -8.94 | -7.27 |
EBT Excluding Unusual Items | -565.71 | -464.71 | -257.01 | -361.02 | -191.54 | 209.07 |
Impairment of Goodwill | - | - | - | - | -353.87 | - |
Gain (Loss) on Sale of Investments | -4.6 | -5.36 | -60.01 | -0.01 | 15.64 | -9.05 |
Gain (Loss) on Sale of Assets | 35.42 | 6.99 | 0.09 | 4.97 | 2.34 | -3.57 |
Asset Writedown | -359.12 | -334.92 | -105.38 | -129.64 | -90.7 | -1.27 |
Legal Settlements | - | - | - | - | -16.58 | -52.84 |
Other Unusual Items | -95.45 | -44.07 | 33.37 | -26.16 | -1.07 | 23.8 |
Pretax Income | -989.45 | -842.07 | -388.95 | -511.86 | -635.78 | 166.14 |
Income Tax Expense | 13.97 | 19.15 | 12.8 | -7.22 | 22.92 | 24.34 |
Earnings From Continuing Operations | -1,003 | -861.22 | -401.75 | -504.65 | -658.7 | 141.8 |
Minority Interest in Earnings | 0.76 | 2.66 | 12.78 | -25.41 | -29.77 | -43.38 |
Net Income | -1,003 | -858.56 | -388.96 | -530.06 | -688.47 | 98.42 |
Net Income to Common | -1,003 | -858.56 | -388.96 | -530.06 | -688.47 | 98.42 |
Net Income Growth | - | - | - | - | - | 28.63% |
Shares Outstanding (Basic) | 659 | 660 | 659 | 663 | 662 | 656 |
Shares Outstanding (Diluted) | 659 | 660 | 659 | 663 | 662 | 656 |
Shares Change (YoY) | 0.40% | 0.18% | -0.50% | 0.09% | 0.89% | 2.90% |
EPS (Basic) | -1.52 | -1.30 | -0.59 | -0.80 | -1.04 | 0.15 |
EPS (Diluted) | -1.52 | -1.30 | -0.59 | -0.80 | -1.04 | 0.15 |
EPS Growth | - | - | - | - | - | 25.00% |
Free Cash Flow | 60.98 | -17.07 | 207.41 | -139.89 | -305.18 | -498.83 |
Free Cash Flow Per Share | 0.09 | -0.03 | 0.32 | -0.21 | -0.46 | -0.76 |
Gross Margin | 19.89% | 21.93% | 32.33% | 24.39% | 24.96% | 31.87% |
Operating Margin | -22.40% | -12.58% | 2.16% | -8.02% | -0.75% | 10.15% |
Profit Margin | -68.16% | -46.19% | -16.92% | -24.24% | -23.18% | 3.20% |
Free Cash Flow Margin | 4.15% | -0.92% | 9.02% | -6.40% | -10.27% | -16.24% |
EBITDA | -121.98 | -15.7 | 282.2 | 60.29 | 125.02 | 447.17 |
EBITDA Margin | -8.29% | -0.84% | 12.27% | 2.76% | 4.21% | 14.56% |
D&A For EBITDA | 207.49 | 218.22 | 232.53 | 235.64 | 147.41 | 135.32 |
EBIT | -329.46 | -233.92 | 49.67 | -175.35 | -22.39 | 311.85 |
EBIT Margin | -22.40% | -12.58% | 2.16% | -8.02% | -0.75% | 10.15% |
Effective Tax Rate | - | - | - | - | - | 14.65% |
Revenue as Reported | 1,471 | 1,859 | 2,299 | 2,187 | 2,971 | 3,072 |
Advertising Expenses | - | 7.78 | 6.33 | 9.46 | 34.1 | 20.55 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.